The usefulness of routine chest radiograph examinations in patients treated with TNF inhibitors for inflammatory arthritis in South Korea
- PMID: 30261981
- DOI: 10.1016/j.rmed.2018.09.005
The usefulness of routine chest radiograph examinations in patients treated with TNF inhibitors for inflammatory arthritis in South Korea
Abstract
Objectives: We aimed to investigate the usefulness of routine chest radiograph (CXR) examinations for patients with inflammatory arthritis treated with a tumor necrosis factor (TNF) inhibitor in terms of (i) the role of CXR in baseline latent tuberculosis infection (LTBI) screening and (ii) detecting asymptomatic active tuberculosis after TNF inhibitor initiation.
Methods: From January 2011 to June 2017, 469 patients with inflammatory arthritis were enrolled in the study at a tertiary referral center in South Korea. At our institution, CXR was performed for all patients undergoing a tuberculin skin test (TST) and/or an interferon-gamma release assay (IGRA) at the LTBI screening visit. LTBI treatment was determined by (i) positive TST or IGRA or (ii) CXR findings suggestive of spontaneously healed tuberculosis. After TNF inhibitor initiation, patients were recommended to undergo CXR at a specified interval.
Results: Of 469 patients, 187 were treated for LTBI. Among them, 181 patients were treated for LTBI because of a positive TST or IGRA result. TST was considered positive if induration size was ≥10 mm. The remaining six patients were considered positive on the basis of CXR findings compatible with spontaneously healed tuberculosis, such as noncalcified nodules with distinct margins and fibrotic linear opacity, despite demonstrating negative results for TST and IGRA. Thus, CXR had a diagnostic value as a baseline LTBI test in 6 (1.3%) patients. After TNF inhibitor initiation, 2 patients who had respiratory symptoms were diagnosed with active tuberculosis. For asymptomatic patients, routine CXR follow-up could not detect any case of active pulmonary tuberculosis within 1 year (n = 219) or after 1 year (n = 217).
Conclusions: CXR should be performed as one of the LTBI screening tests for patients with inflammatory arthritis in a tuberculosis-prevalent country. However, after TNF inhibitor treatment, routine CXR follow-up was not advantageous.
Keywords: Chest radiograph; Inflammatory arthritis; Latent tuberculous infection; TNF inhibitor; Tuberculosis.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Comparison of latent tuberculosis infection screening strategies before tumor necrosis factor inhibitor treatment in inflammatory arthritis: IGRA-alone versus combination of TST and IGRA.PLoS One. 2018 Jul 5;13(7):e0198756. doi: 10.1371/journal.pone.0198756. eCollection 2018. PLoS One. 2018. PMID: 29975703 Free PMC article.
-
Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.Clin Rheumatol. 2011 Dec;30(12):1535-41. doi: 10.1007/s10067-011-1771-9. Epub 2011 May 10. Clin Rheumatol. 2011. PMID: 21556777
-
Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients.BMC Pulm Med. 2020 Aug 31;20(1):232. doi: 10.1186/s12890-020-01274-9. BMC Pulm Med. 2020. PMID: 32867745 Free PMC article.
-
[TNF inhibitors].Nihon Rinsho. 2016 Jun;74(6):957-62. Nihon Rinsho. 2016. PMID: 27311185 Review. Japanese.
-
Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.J Rheumatol. 2011 Jul;38(7):1234-43. doi: 10.3899/jrheum.100623. Epub 2011 Apr 1. J Rheumatol. 2011. PMID: 21459944 Review.
Cited by
-
Latent Tuberculosis Infection and COVID-19: Analysis of a Cohort of Patients from Careggi University Hospital (Florence, Italy).Infect Dis Rep. 2023 Dec 10;15(6):758-765. doi: 10.3390/idr15060068. Infect Dis Rep. 2023. PMID: 38131881 Free PMC article.
-
Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents.Front Immunol. 2025 Feb 3;16:1494283. doi: 10.3389/fimmu.2025.1494283. eCollection 2025. Front Immunol. 2025. PMID: 39963138 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical